Since loss of JAK1 induced tumor resistance to IFNs in vitro, we examined whether it altered the therapeutic effects of IFN-α in vivo by treating mice bearing B16/OVA or B16/OVA-JAK1−/− cell-derived tumors with IFN-α4. Here, JAK1 is linked to neoplasm.